Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion ...
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
The stock market is divided, with the Nasdaq and S&P 500 breaking support but many sectors thriving. Google and Amazon AI spending stunned. Bitcoin plunged.
MedImpact expands access and affordability across healthcare with a low-cost alternative to one of the most prescribed and expensive biologics in the US MedImpact Holdings, Inc. today announced the ...
Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net ...
Dr. Dan Thomson shares essential tips for injections, needle selection and syringe maintenance to ensure herd health and ...
Guerbet's innovation, Elucirem™ is the first gadolinium-based contrast agent approved at half dose of gadolinium, and with ...
Meijer announced today that it is making two of the most sought-after GLP-1 medications, Wegovy® and Ozempic® (semaglutide), more affordable for its customers by accepting savings programs available ...
Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising superstar Skyrizi. Despite the fall of what was once the world’s top-selling ...
Florida’s rules for animal euthanasia, created in the 1990s, span a full page. Its guidance for executions by lethal ...
Attorney General Pam Bondi’s demand that Minnesota hand over sensitive voter registration records to the federal government amid tensions over ICE and immigration enforcement underscores the ...
LIBERTY-AFRS-AIMS met its primary endpoint with a 50% reduction in CT sinus opacification at week 52 versus 10% with placebo (P<.0001).